Impel Pharmaceuticals
5 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD (NCT05163717) | Impel Pharmaceuticals | 2022-06-23 |
| Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101 (NCT03624322) | Impel Pharmaceuticals | 2018-08-05 |
| Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301) (NCT03557333) | Impel Pharmaceuticals | 2018-07-13 |
| Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal (NCT03541356) | Impel Pharmaceuticals | 2018-05-08 |
| Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults (NCT03401346) | Impel Pharmaceuticals | 2017-10-19 |
Track Impel Pharmaceuticals automatically
Every clearance here is in the API, with alerts when new ones post.